Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H24N2O2.ClH |
| Molecular Weight | 312.835 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=CC=CC(C)=C1NC(=O)C2CCCCN2CCO
InChI
InChIKey=ZBNGGCXOSMHCEV-UHFFFAOYSA-N
InChI=1S/C16H24N2O2.ClH/c1-12-6-5-7-13(2)15(12)17-16(20)14-8-3-4-9-18(14)10-11-19;/h5-7,14,19H,3-4,8-11H2,1-2H3,(H,17,20);1H
| Molecular Formula | C16H24N2O2 |
| Molecular Weight | 276.374 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Droxicainide is a new antiarrhythmic agent. When given intravenously droxicainide suppressed ouabain-induced arrhythmias in pentobarbital-anesthetized guinea pigs. The initial experimental studies reported that droxicainide appears to have a more potent antiarrhythmic activity and fewer side effects than lidocaine. In local anesthetic tests and following intradermal administration to rabbits, droxicainide produced less local tissue irritation than lidocaine. Droxicainide is a class 1 anti-arrhythmic drug.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparison of electrophysiological and mechanical effects of droxicainide and lidocaine on heart muscle isolated from rats. | 1984-10 |
|
| The acute antiarrhythmic effects of droxicainide and lidocaine in unanesthetized dogs. | 1984-03-01 |
|
| Effects of lidocaine and droxicainide on myocardial necrosis: a comparative study. | 1983-06 |
|
| Pharmacological studies on droxicainide, a new antiarrhythmic agent. | 1983 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6853899
2.5 mg/kg as a bolus and then as a continuous infusion for 6 hours (1.4 mg/kg).
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:50:12 GMT 2025
by
admin
on
Mon Mar 31 22:50:12 GMT 2025
|
| Record UNII |
91801A0812
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
149572-05-4
Created by
admin on Mon Mar 31 22:50:12 GMT 2025 , Edited by admin on Mon Mar 31 22:50:12 GMT 2025
|
PRIMARY | |||
|
3060807
Created by
admin on Mon Mar 31 22:50:12 GMT 2025 , Edited by admin on Mon Mar 31 22:50:12 GMT 2025
|
PRIMARY | |||
|
91801A0812
Created by
admin on Mon Mar 31 22:50:12 GMT 2025 , Edited by admin on Mon Mar 31 22:50:12 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |